Shanghai Anbison Laboratories Co., Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation dapagliflozin metformin extended-release tablets (specification: 5 mg/500 mg, licensee: Shanghai Anbisheng Pharmaceutical Technology Co., Ltd.) and the reference preparation dapagliflozin metformin extended-release tablets (XIGDUO® XR, specification: 5 mg/500 mg, licensee: AstraZeneca AB) in healthy subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation dapagliflozin metformin extended-release tablets (specification: 5 mg/500 mg) and the reference preparation dapagliflozin metformin extended-release tablets (XIGDUO® XR, specification: 5 mg/500 mg) in healthy subjects.

Primary objective: To compare the differences in absorption degree and speed of toremifene citrate tablets (specification: 60 mg (in toremifene)) provided by Shanghai Anbisheng Pharmaceutical Technology Co., Ltd. and toremifene citrate tablets (specification: 60 mg (in toremifene), trade name: Fareston®) produced by Orion Corporation of Finland under fasting and postprandial administration conditions in healthy people. Secondary objective: To evaluate the safety of toremifene citrate tablets (specification: 60 mg (in toremifene)) provided by Shanghai Anbisheng Pharmaceutical Technology Co., Ltd. and toremifene citrate tablets (specification: 60 mg (in toremifene), trade name: Fareston®) produced by Orion Corporation of Finland under fasting and postprandial administration conditions.

Main purpose: Using the flurbiprofen gel patch (containing 40 mg of flurbiprofen per patch (area 13.6 cm × 10.0 cm, containing 12 g of paste), trade name Zepolas®) of the licensed manufacturer MIKASA SEIYAKU CO., LTD as the reference preparation, and the flurbiprofen gel patch (containing 12 g of paste per patch (area 13.6 cm × 10.0 cm), containing 40 mg of flurbiprofen) developed by Shanghai Anbisheng Pharmaceutical Technology Co., Ltd. as the test preparation, the bioequivalence of the two preparations under topical conditions in Chinese healthy subjects was evaluated. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in Chinese healthy subjects; 2) To evaluate the adhesion of the test preparation and the reference preparation during the medication process of Chinese healthy subjects; 3) To evaluate the skin reactivity of the test preparation and the reference preparation to Chinese healthy subjects.